Evolus (EOLS) Competitors

Kymera Therapeutics (NASDAQ:KYMR) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.

Which has more volatility and risk, KYMR or EOLS?

Kymera Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Which has preferable valuation and earnings, KYMR or EOLS?

Evolus has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$78.59M	36.36	-$146.96M	-$2.34	-18.86
Evolus	$202.09M	4.43	-$61.69M	-$0.91	-15.53

Does the MarketBeat Community favor KYMR or EOLS?

Evolus received 299 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 72.69% of users gave Evolus an outperform vote while only 53.40% of users gave Kymera Therapeutics an outperform vote.

Company	Underperform	Outperform
Kymera Therapeutics	Outperform Votes 55 53.40%	Underperform Votes 48 46.60%
Evolus	Outperform Votes 354 72.69%	Underperform Votes 133 27.31%

Does the media refer more to KYMR or EOLS?

In the previous week, Evolus had 12 more articles in the media than Kymera Therapeutics. MarketBeat recorded 19 mentions for Evolus and 7 mentions for Kymera Therapeutics. Evolus' average media sentiment score of 0.63 beat Kymera Therapeutics' score of 0.60 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	7 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer KYMR or EOLS?

Kymera Therapeutics presently has a consensus target price of $55.06, suggesting a potential upside of 24.77%. Evolus has a consensus target price of $23.00, suggesting a potential upside of 62.77%. Given Evolus' stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Evolus	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is KYMR or EOLS more profitable?

Evolus has a net margin of -22.33% compared to Kymera Therapeutics' net margin of -191.26%. Kymera Therapeutics' return on equity of -24.96% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-191.26%	-24.96%	-20.27%
Evolus	-22.33%	-847.60%	-22.15%

Do institutionals and insiders hold more shares of KYMR or EOLS?

90.7% of Evolus shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by insiders. Comparatively, 6.1% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Evolus beats Kymera Therapeutics on 11 of the 18 factors compared between the two stocks.